AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Over

Curaleaf Holdings (OTC: CURLF) is een van de grootste multi-state cannabisoperatoren in de Verenigde Staten, met teelt-, verwerkings- en retail-dispensariumactiviteiten in talrijke staten en een significante internationale aanwezigheid in Europa via de overname van EMMAC Life Sciences. Het bedrijf heeft een verticaal geïntegreerd platform gebouwd met een portefeuille van eigen merken waaronder Select, Grassroots en Find, en genereert een van de hoogste omzetten van elk Amerikaans cannabisbedrijf. Als belegging biedt Curaleaf directe blootstelling aan de Amerikaanse cannabismarkt met operationele schaalgrootte en geografische diversificatie, hoewel de OTC-notering, aanhoudende winstgevingsuitdagingen in de sector en de onzekere tijdlijn voor federale hervorming belangrijke overwegingen voor beleggers blijven.

Cannabisaandelen

Curaleaf is een toonaangevend cannabisaandeel dat één van de grootste "plant-touching" marihuana-exploitanten in de Verenigde Staten vertegenwoordigt, met een voetafdruk van meerdere staten in detailhandel en teelt die het goed kan helpen bij elke federale legalisering of herschikking van cannabis.

Key Financials CURA

Prijs $3.31
Wijziging (1D) +2.16%
Wijziging (30D) -7.54%
Wijziging (60D) +21.25%
Wijziging (90D) -24.43%
Wijziging (180D) +171.31%
Wijziging (1Y) +57.62%
P/E-verhouding -12.26
EPS (TTM) $-0.27
52-weekse bandbreedte $0.99 — $6.98
50-daags MA $3.68
Volume 355.4K

Data updated Feb 15 · Source: Twelve Data

4.2
2 reviews
Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Claude Opus 4.6
AI Review
4.2/5

Curaleaf Holdings is the largest multi-state cannabis operator in the U.S. by revenue, with operations spanning cultivation, processing, and retail across numerous states and international markets. The company's scale provides meaningful competitive advantages in procurement, branding, and regulatory navigation.

The bull case centers on Curaleaf's market leadership position and potential federal rescheduling or legalization catalysts, evidenced by the 171% gain over six months as sentiment improved. Its extensive retail footprint and brand portfolio (Select, Grassroots) create durable competitive moats in a fragmented industry.

However, the bear case is significant. The negative P/E ratio of -12.26 and EPS of -$0.27 reflect ongoing profitability challenges common across cannabis MSOs. The stock trades well below its 52-week high of $6.98, and the 24% decline over 90 days suggests fading momentum as rescheduling timelines remain uncertain. Heavy debt loads and 280E tax burdens continue to pressure cash flows.

Curaleaf remains a top-tier cannabis play for investors with high risk tolerance, but profitability must materialize to justify current valuations. Regulatory catalysts remain the key swing factor.

Performance
4
Management Quality
3.8
Valuation
3.4
Fundamentals
3.2
Risk Profile
2.8
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
4.2/5

Curaleaf Holdings maintains its status as a top-tier U.S. Multi-State Operator (MSO), distinguished by its massive geographic footprint and strategic expansion into the European market. For investors, the primary thesis rests on Curaleaf's scale advantage and its ability to capitalize on potential regulatory shifts, such as federal rescheduling. However, the company's financials reflect the broader challenges of the cannabis industry; with a trailing EPS of -$0.27 and a negative P/E ratio, profitability remains hindered by tax burdens and capital-intensive growth. The stock currently trades at $3.24, which is below its 50-day moving average of $3.68, indicating recent bearish momentum despite trading significantly above its 52-week low of $0.99. While Curaleaf represents one of the more stable vehicles for exposure to the cannabis sector, it remains a speculative investment requiring patience for regulatory clarity and improved cash flow generation.

Feb 11, 2026
Curaleaf Holdings Screenshot

Added: Feb 10, 2026

curaleaf.com

Latest from Otrai